CARLSBAD, Calif., May 15, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 6, 2024.
The agenda for the event is as follows:
- 5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders
- All stockholders of record at the close of business on April 8, 2024, are invited to participate in the virtual Annual Meeting webcast, which will be broadcast live at http://www.virtualshareholdermeeting.com/IONS2024.
- Stockholders of record will receive an official proxy card from their brokerage firm. Each proxy card contains a 16-digit control number required to log-in, vote and submit questions during the webcast.
- Ionis does not provide proxy cards or have access to proxy card information, including 16-digit control numbers. For help obtaining a proxy card or to locate their control number or for instructions to access the webcast, stockholders of record should contact their brokerage firm before Thursday, May 23.
- A help line will be available on the registration page of the live webcast for participants requiring technical assistance in accessing or participating during the live event. There will not be a replay of this session.
- All stockholders of record at the close of business on April 8, 2024, are invited to participate in the virtual Annual Meeting webcast, which will be broadcast live at http://www.virtualshareholdermeeting.com/IONS2024.
- 5:30 p.m. ET (2:30 p.m. PT) – Virtual corporate update
- Brett P. Monia, Ph.D., Ionis' chief executive officer, will provide a general corporate update followed by a question-and-answer session.
- All interested parties may access the webcast live at https://event.webcasts.com/starthere.jsp?ei=1659973&tp_key=9ca016319a. An archived replay of the webcast will be posted for a limited time following the meeting at that same address.
- Questions for management may be submitted in advance of the webcast and will be addressed during the question-and-answer portion of the webcast. Please submit questions via email to [email protected] by Tuesday, June 4. Questions not addressed during the webcast will be answered by email following the meeting.
- Brett P. Monia, Ph.D., Ionis' chief executive officer, will provide a general corporate update followed by a question-and-answer session.
About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionispharma.com and follow us on X (Twitter) and LinkedIn.
Ionis Pharmaceuticals Investor Contact:
D. Wade Walke, Ph.D. – [email protected] – 760-603-2331
Ionis Pharmaceuticals Media Contact:
Hayley Soffer – [email protected] – 760-603-4679
SOURCE Ionis Pharmaceuticals, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article